Japan· JP-6429007F1033
アルベンダゾール
A albendazole product containing アルベンダゾール, registered in Japan by グラクソ・スミスクライン, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Albendazole is registered in 10 of 19 countries.
Countries holding a registration under ATC P02CA03 (albendazole), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 6 of them publish a price we can compare per daily dose
Albendazole · ATC P02CA03
10 / 19 countries
- Czechiaprice
- Franceprice
- Germany
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of albendazole costs, country by country.
Normalised to the WHO defined daily dose (0.8 g), the median price runs from $5.63 in France to $36.54 in Switzerland — a ×6.5 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Albendazole · price per daily dose (0.8 g)
USD · FX 28 Sept 2026
- CH Switzerland$36.54
- FR France$5.63
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- アルベンダゾール
- Manufacturer
- グラクソ・スミスクライン
- Country
- Japan (JP)
- ATC code
- P02CA03
- ATC class
- Albendazole
- Defined daily dose
- 0.8 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
114 interactions on record for albendazole.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Albendazole · interactions on record
114 records
- 3 severe
- 102 moderate
- 9 minor
Most severe, free to view
- CladribineL01BB04severe
- CladribineL04AA40severe
- ClozapineN05AH02severe
- AprepitantA04AD12moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under P02CA03
Albendazole, as other registers publish it.
- NorwayAlbendazol micro labsMicro Labs
- GermanyAlbendazol Micro LabsMicro Labs Gmbh
- CzechiaALBENDAZOL VIM SPECTRUM
- United StatesAlbendazoleGolden State Medical Supply, Inc.
- United StatesAlbendazoleAlembic Pharmaceuticals Inc.
- United StatesAlbendazoleEdenbridge Pharmaceuticals LLC.
- United StatesAlbendazoleAmneal Pharmaceuticals of New York LLC
- United StatesAlbendazoleActavis Pharma, Inc.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b26f422a-146d-42de-9c10-518480ec846c GET /v1/drugs/b26f422a-146d-42de-9c10-518480ec846c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２００ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "6429007F1033",
"category": "内用薬",
"price_yen": 312.3,
"generic_name": "アルベンダゾール",
"product_name_jp": null,
"therapeutic_class": "6429",
"transitional_expiry": null
}See everything about albendazole.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.